LACY GUEDON: Open Payments
NPI 1922484757 · WINNSBORO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$668 in 31 payments from 10 companies in 2025. Trend: 2023 $465 · 2024 $682 · 2025 $668
Food & beverage: $668
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $133 |
| Janssen Pharmaceuticals, Inc | 6 | $108 |
| ABBVIE INC. | 4 | $82 |
| Vanda Pharmaceuticals Inc. | 3 | $81 |
| Alkermes, Inc. | 3 | $58 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| Corium, LLC | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: REXULTI, INVEGA SUSTENNA, VRAYLAR, FANAPT, ARISTADA, Auvelity, Azstarys, COBENFY.
Industry payments across LA — which companies pay providers there.
